Assessment of Circulating Fubctional Mitochondrias in Vitiligo Patients

Study Overview
=================
Brief Summary
-----------------
To compare the level of circulating functional mitochondria in the serum of vitiligo patients as compared to controls

Official Title
-----------------
Assessment of Circulating Fubctional Mitochondrias in Vitiligo Patients as Compared to Controls

Conditions
-----------------
Skin and Connective Tissue Diseases

Intervention / Treatment
-----------------
* Other: Non segmental vitiligo
* Other: Health Volunteers


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with non segmental vitiligo, atopic dermatitis, psoriais, alopecia areata, 1st degree relative of vitiligo patients. Exclusion Criteria: segmental or mixed vitiligo, personnal history of other autoimmune disorders, oral use of antioxidant, pregant women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Patients with non segmental vitiligo compared to healthy volunteers (1st degree family of vitiligo patients) atopic dermatitis, psoriasis and alopecia areata patients
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Vitiligo Group<br>If the subject consents and they meet all the criteria a 20 ml blood sample will be taken. | Other: Non segmental vitiligo<br>* The subjects will be selected from among those presenting for the consultation or hospitalization of the Dermatology department of the CHU de Nice. All necessary information will be given to the subjects and a briefing note will be given to them. A reflection period will be left for the subjects to sign the informed consent, and if necessary, another appointment will be scheduled for the inclusion visit. The Investigator: Inform the subject of the goals, constraints and risks of the study and obtain written consent. Conduct an examination of the subject's medical history Will verify that the subject meets all inclusion criteria and does not present any of the criteria for not including. If the subject consents and they meet all the criteria a 20 ml blood sample will be taken.<br>|
| Other: Volunteers Group<br>If the subject consents and they meet all the criteria a 20 ml blood sample will be taken. | Other: Health Volunteers<br>* The subjects will be selected from among those presenting for the consultation or hospitalization of the Dermatology department of the CHU de Nice. The family control subjects will be recruited from the vitiligos patients coming into our department. All necessary information will be given to the subjects and a briefing note will be given to them. A reflection period will be left for the subjects to sign the informed consent, and if necessary, another appointment will be scheduled for the inclusion visit. The Investigator: Inform the subject of the goals, constraints and risks of the study and obtain written consent. Conduct an examination of the subject's medical history Will verify that the subject meets all inclusion criteria and does not present any of the criteria for not including. If the subject consents and they meet all the criteria a 20 ml blood sample will be taken.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total number of circulating functionnal mitochondria (CFM) in the plasma | Level of CFM in vitiligo serum as compared to controls | at baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| measuring the functionality of circulating mitochondria | Functional analysis of CFM in vitiligo patients as compared to controls analyzed by MFI Mito Tracker | At baseline |